Radiosynthesis of (R,S)-[
PET imaging
TSPO receptor
[18F]GE180
[18F]GE387
neuroinflammation biomarkers
Journal
ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013
Informations de publication
Date de publication:
06 05 2019
06 05 2019
Historique:
received:
10
01
2019
revised:
26
02
2019
pubmed:
23
3
2019
medline:
18
2
2020
entrez:
23
3
2019
Statut:
ppublish
Résumé
Translocator protein (TSPO) is a biomarker of neuroinflammation, which is a hallmark of many neurodegenerative diseases and has been exploited as a positron emission tomography (PET) target. Carbon-11-labelled PK11195 remains the most applied agent for imaging TSPO, despite its short-lived isotope and low brain permeability. Second-generation radiotracers show variance in affinity amongst subjects (low-, mixed-, and high-affinity binders) caused by the genetic polymorphism (rs6971) of the TSPO gene. To overcome these limitations, a new structural scaffold was explored based on the TSPO pharmacophore, and the analogue with a low-affinity binder/high-affinity binder (LAB/HAB) ratio similar (1.2 vs. 1.3) to that of (R)-[
Identifiants
pubmed: 30900397
doi: 10.1002/cmdc.201900023
pmc: PMC6563049
doi:
Substances chimiques
Fluorine Radioisotopes
0
Radiopharmaceuticals
0
Receptors, GABA
0
TSPO protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
982-993Subventions
Organisme : Medical Research Council
ID : MR/K02308X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : RG70550
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : RG46503
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_16040
Pays : United Kingdom
Informations de copyright
© 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
Références
Nat Rev Drug Discov. 2010 Dec;9(12):971-88
pubmed: 21119734
Biochem Soc Trans. 2015 Aug;43(4):586-92
pubmed: 26551697
Technol Cancer Res Treat. 2006 Aug;5(4):337-41
pubmed: 16866564
Contrast Media Mol Imaging. 2017 Sep 25;2017:6592139
pubmed: 29114179
Bioorg Med Chem Lett. 2012 Feb 1;22(3):1308-13
pubmed: 22244939
J Org Chem. 2002 Apr 5;67(7):2375-7
pubmed: 11925260
J Cereb Blood Flow Metab. 2012 Jul;32(7):1393-415
pubmed: 22549622
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1423-1431
pubmed: 29523925
J Nucl Med. 2018 Aug;59(8):1260-1266
pubmed: 29348317
J Nucl Med. 2016 Feb;57(2):165-8
pubmed: 26697963
J Nucl Med. 2016 Nov;57(11):1753-1759
pubmed: 27261523
Angew Chem Int Ed Engl. 2005 Feb 18;44(9):1378-82
pubmed: 15674985
Medchemcomm. 2016 Nov 15;8(1):202-210
pubmed: 30108706
Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2201-2210
pubmed: 27349244
ChemMedChem. 2019 May 6;14(9):982-993
pubmed: 30900397
Bioconjug Chem. 2013 Sep 18;24(9):1415-28
pubmed: 23837837
Life Sci. 1983 Aug 1;33(5):449-57
pubmed: 6308375
J Org Chem. 2011 May 20;76(10):4168-72
pubmed: 21491889
Bioorg Med Chem. 2004 Jul 1;12(13):3569-80
pubmed: 15186841